AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ABIVAX

Report Publication Announcement Sep 29, 2023

1063_rns_2023-09-29_4bcd9ce7-5617-4e0d-947d-e69eb29ab699.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

News Details

Corporate | 29 September 2023 18:00

Abivax announces the release of its 2023 half-year financial report

EQS-News: ABIVAX / Key word(s): Half Year Report

Abivax announces the release of its 2023 half-year financial report

29.09.2023 / 18:00 CET/CEST

The issuer is solely responsible for the content of this announcement.

Abivax announces the release of its 2023 half-year financial report

PARIS, France, September 29, 2023 – 6:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announces today the release of its 2023 half-year financial report.

The 2023 half-year financial report is available on the website of the Company ( www.abivax.com – “Investors” ).

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Based in France and the U.S., Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at www.abivax.com . Follow us on X, formerly Twitter, @ABIVAX_.

Contacts

Investor Relations

Abivax

Patrick Malloy

[email protected]

+1 847 987 4878
Investors Relations US

LifeSci Advisors

Ligia Vela-Reid

[email protected]

+44 7413 825310
Investors Relations France

Seitosei Actifin

Ghislaine Gasparetto

[email protected]

+33 6 21 10 49 24
Investor Relations Europe

MC Services AG

Dr. Solveigh Mähler

[email protected]

+49 211 529 252 19

29.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com


show this

Talk to a Data Expert

Have a question? We'll get back to you promptly.